Lipoprotein Assessment in the twenty-first Century

• Diego Lucero ^[1] ; Anna Wolska ^[2] ; Zahra Aligabi ^[1] ; Sarah Turecamo ^[2] ; Alan T. Remaley ^[1]
  1. [1] Lipoprotein Metabolism Laboratory, Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 5D09, Bethesda, MD 20892, USA
  2. [2] Heart Disease Phenomics Laboratory, Epidemiology and Community Health Branch, National Heart, Lung, and Blood Institute. National Institutes of Health, 9000 Rockville Pike, Building 10, Room 5N323, Bethesda, MD 20892, USA
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 51, Nº. 3, 2022, págs. 459-481
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Based on decades of both basic science and epidemiologic research, there is overwhelming evidence for the causal relationship between high levels of cholesterol, especially low-density lipoprotein cholesterol and cardiovascular disease. Risk evaluation and monitoring the response to lipid-lowering therapies are heavily dependent on the accurate assessment of plasma lipoproteins in the clinical laboratory. This article provides an update of lipoprotein metabolism as it relates to atherosclerosis and how diagnostic measures of lipids and lipoproteins can serve as markers of cardiovascular risk, with a focus on recent advances in cardiovascular risk marker testing.